Bharat Biotech

iNNCOVACC is the world’s first intra-nasal COVID-19 vaccine to receive approval for the primary two-dose schedule, and as a…

iNCOVACC is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule, and heterologous…

The findings of the study have been published on bioRxiv, a pre-print server and have not been peer reviewed

CEPI’s funding will support the consortium as it seeks to establish preclinical and clinical proof of concept for an adjuvanted…

Hundred per cent of test serum samples showed neutralisation of the Delta variant and more than 90 per cent of serum samples…

The phase 2, double-blind, randomised controlled COVAXIN® trial demonstrated long-term safety with no serious adverse events

Covaxin is formulated uniquely such that the same dosage can be administered to adults and children

The app provides free COVID patient consultation anywhere, 24x7, 365 days a year

These 44 crore doses of COVID-19 vaccines will be delivered by their makers between August and December 2021

According to WHO, submissions to it for prequalification or listing under the emergency use procedure are confidential